Baricitinib Reduces Mortality in Critically Ill Adults With COVID-19
FRIDAY, Feb. 18, 2022 (HealthDay News) -- For critically ill hospitalized patients with COVID-19 receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, baricitinib plus standard of care is associated with reduced mortality, according to a study published online Feb. 3 in The Lancet Respiratory Medicine.
E. Wesley Ely, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues conducted a trial in 18 hospitals to examine the efficacy and safety of baricitinib plus standard of care for critically ill hospitalized adults with COVID-19 receiving invasive mechanical ventilation or extracorporeal membrane oxygenation. A total of 101 patients were enrolled and randomly assigned to either baricitinib or placebo plus standard of care (51 and 50 patients, respectively).
The researchers observed a significant reduction in 28-day all-cause mortality with baricitinib treatment versus placebo (39 versus 58 percent; hazard ratio, 0.54). There was also a significant reduction seen in 60-day mortality in the baricitinib group versus the placebo group (45 versus 62 percent; hazard ratio, 0.56). At days 28 and 60, one additional death was prevented for every six baricitinib-treated patients versus placebo-treated patients. No significant difference was seen between the groups in the number of ventilator-free days. The mean duration of hospitalization did not differ significantly for baricitinib- and placebo-treated patients.
"These results are consistent with the reduction in mortality observed in the less severely ill hospitalized patients in the primary COV-BARRIER study population and further support the use of baricitinib in hospitalized adults with COVID-19," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures baricitinib and funded the study.
Related Posts
FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans
THURSDAY, Sept. 23, 2021 (HealthDay News) -- The U.S. Food and Drug...
Another Study Finds Bogus ‘Conversion Therapy’ Harms LGBTQ Teens
TUESDAY, March 8, 2022 (HealthDay News) -- There are serious mental harms and...
FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC
THURSDAY, May 4, 2023 (HealthDay News) -- Treatment with trifluridine-tipiracil...
Más mujeres con educación universitaria tienen hijos fuera del matrimonio
MARTES, 7 de septiembre de 2021 (HealthDay News) -- Primero viene el amor....